Time to Sell the News on Moderna (NASDAQ: MRNA) Stock

Monday, December 28, 2020 | Jea Yu
Time to Sell the News on Moderna (NASDAQ: MRNA) Stock Clinical stage biotechnology company Moderna, Inc. (NASDAQ: MRNA) stock has been in the forefront during the pandemic in the battle against COVID-19. Shares are still up over 500% year-to-date (YTD) as vaccine approval and distribution is well underway. While shares have peaked at $178.50, the sell-the-news reaction is also underway with much more downside to follow. Investors who may have taken a position in the run-up may consider utilizing opportunistic exit levels to bank the profits and trim down exposure.

mRNA-1273 Vaccine

The Moderna COVID-19 vaccine can be stored at minus 20 degrees Celsius and is stable at that temperature for six months. The six months is only because that’s the amount of data that’s been collected so far. As the Company collects more data, the time can increase. The minus 20 degrees is the same temperature for keeping ice cream frozen, making it easier to ship and store than the Pfizer (NYSE: PFE) vaccine. The Moderna vaccine can be stored at refrigerator temperatures for 30-days and remain stable for 12-hours at room temperature. The U.S. government granted nearly $1 billion for help in the development of the vaccine through Phase 3 clinical trials. That is reflected in the pricing of the vaccine for the U.S. government when including BARDA funding at $25 per dose and $15.25 per dose excluding it. Since it was a grant, there are no royalties due back to the U.S. government as clarified by Moderna Senior Vice President, Lavina Talukdar, in a Q&A session at the B<O Growth and ESG Conference Call on Dec. 9, 2020.

FDA Approval and Distribution Rollout

On Dec. 21, 2020, the U.S. Food and Drug Administration (FDA) authorized the emergency use of mRNA-1273, COVID-19 vaccine, for use in individuals 18 and over. Under the U.S. Department of Defense in partnership with U.S. Department of Health and Human Services and U.S. Centers for Disease Control’s Operation Warp Speed program, the distribution prioritizes certain portions of the population identified under Advisory Committee on Immunization Practices. Approximately 20 million doses are expected to be delivered to the U.S. government by the end of December and 85 million to 100 million available in the U.S. by Q1 2021. Priority is given to health care personnel treating COVID-19 patients and residents in long-term healthcare facilities. On Dec. 23, 2020, Health Canada authorized the Moderna COVID-19 vaccine for the immunization of people 18 years of age and older under an Interim Order. Moderna also stated that its vaccine will protect against the new COVID-19 strain variant discovered in the U.K.

Moderna Valuations

Estimated revenues from the COVID-19 vaccine sales are expected to top $11 billion for 2021. Based on price to sales, Moderna is currently trading 4.41X estimate 2021 revenues versus Pfizer at 4.31X price/sales. Pfizer shares have already sold off as the market prices in vaccine sales. Since the COVID-19 vaccines are a one-time event, revenues will tail off significantly especially as new COVID-19 vaccines get approval and distribution including Astra Zeneca PLC (NYSE: AZN) on the horizon. Moderna currently trades at 185X price/sales and was a $20 stock at the start of the year. Moderna has many drugs in the pipeline and the bolstering of free cash flow from COVID-19 improves its financial position even to a point of being a potential acquisition target, the main driver for shares has been the COVID-19 vaccine. The news is out and it’s time to sell as shares return to reality.

Insider Trading Resumes

On Dec. 23, 2020, Moderna lifted the suspension of 10b5-1 trading plans that were implemented in late summer 2019 as per a Form 8-K filing. This enables board members and executives to resume trading through new or amended plans. Due to the massive run up in shares, many insiders may be on the hook for lofty capital gains tax liabilities especially if part of compensation packages. This could result in automated selling to cover the liabilities as more shares come to the market. From prudent investors who took entry into the rollercoaster ride up on Moderna shares, it’s prudent to consider ringing the register to lock in some or all of the profits, insiders are already planning it through the 10b5-1 trading plans at the very least to meet tax liabilities.

Time to Sell the News on Moderna (NASDAQ: MRNA) Stock

 MRNA Opportunistic Exit Levels

Using the rifle charts on the monthly and weekly time frames provides a broader view of the price action playing field for MRNA shares. The monthly stochastic has stalled below the 80-band. The monthly 5-period moving average (MA) support is at $95.85 with the upper Bollinger Bands (BBs) at $145.52. Gravity takes toll when stocks fall back under the upper BBs, like a spaceship reentering the earth’s atmosphere. Once the monthly 5-period MA tests, it may coil, but that’s 30% lower from where it’s trading currently. The weekly rifle chart has lost momentum as shares triggered a weekly market structure high trigger under $147.20 falling under the weekly 5-period MA at $140.02 setting up a channel tightening back towards the weekly 15-period ma near $97. Share coiled off the  currently $114.71 Fibonacci (fib) level. Prudent investors can utilize the coils to trim exposure at opportunistic exit price levels from $126.50 fib to the $145.22 monthly upper BBs with a trail-stop under $101.70. Long-term investors seeking to hold shares can considering selling covered calls at elevated premiums to buffer potential downside.      



7 Lithium Stocks That Will Power the Electric Vehicle Boom

Demand for lithium is set to increase exponentially in the next few years. In fact, according to Statista, demand for lithium may very well double to 820,000 tons in that time. Some of that demand will come from companies that are manufacturing the batteries that we use every day. For example, lithium is an essential component of the batteries that power our mobile devices.

But the real growth will come as the United States goes all-in on electric vehicles (EVs). The Biden administration recently announced plans to have the U.S. government’s fleet of over 600,000 vehicles converted to EVs.

And as you’re aware, EV stocks are in a bubble of some sort at the moment. Some of that is due to the increasing number of companies that went public last year. However, as investors are beginning to realize, not all of these companies will be the next Tesla. In fact, some of these companies may never be successful at bringing an EV to market, at least not at the scale that will be required.

The ones that do make it will need lithium and lots of it. To help you sift through the best lithium stocks to buy, we’ve put together this special presentation.

View the "7 Lithium Stocks That Will Power the Electric Vehicle Boom".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Moderna (MRNA)1.6$139.23-1.2%N/A-85.94Hold$149.65
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.